Clinical trial · Interventional
Effects of Minimal-Flow Sevoflurane and Multimodal Analgesia in Head and Neck Cancer Surgery
Anesthetic-sparing and Renal Protection Effects of Minimal-flow Sevoflurane Anesthesia and Multimodal Analgesia Using a Mixture of Dexmedetomidine-ketamine-lidocaine in Head and Neck Cancer Patients With Free Flap Microvascular Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the anesthetic-sparing and renal protection effects of minimal-flow sevoflurane anesthesia combined with multimodal analgesia using dexmedetomidine, ketamine, and lidocaine in head and neck cancer patients undergoing free flap microvascular surgery. The 2x2 factorial randomized controlled trial aims to compare sevoflurane usage and renal function changes with different fresh gas flow rates and multimodal analgesia.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Kidney Injury | — | UNRESOLVED | — |
| Anesthesia | — | UNRESOLVED | — |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Multimodal Analgesia | — | UNRESOLVED | — |
| Renal Protection | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Minimal flow sevoflurane | Device | — | UNRESOLVED |
| Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Group 1 (HL-D)
- description
- Fresh gas flow at 0.5 L/min with dexmedetomidine-ketamine-lidocaine mixture
- interventionNames
- Drug: Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture
- Device: Minimal flow sevoflurane
- type
- EXPERIMENTAL
- label
- Group 2 (HL-ND)
- description
- Fresh gas flow at 0.5 L/min with placebo normal saline
- interventionNames
- Device: Minimal flow sevoflurane
- type
- EXPERIMENTAL
- label
- Group 3 (L-D)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18-99 years * Scheduled for head and neck cancer tumor resection and free flap reconstruction surgery Exclusion Criteria: * Preoperative tracheostomy * History of previous head and neck cancer tumor resection * Anemia (hematocrit \<30% or recent transfusion) * Hypertension on ACEI/ARB medications * Significant medical conditions (e.g., NYHA class 3 or 4 heart failure, eGFR \<60 ml/min/1.73 m², Child B or C liver failure, severe respiratory disorders, pre-existing cognitive impairment) * ASA physical status 4 or 5 * Allergies to sevoflurane, dexmedetomidine, ketamine, or lidocaine
References
Publications (0)
Data not yet available